Poly-ICLC is under clinical development by Oncovir and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback